These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1378883)

  • 1. De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus.
    Li P; Kuiper LJ; Stephenson AJ; Burrell CJ
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():955-9. PubMed ID: 1378883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
    Larder BA; Kemp SD; Purifoy DJ
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4803-7. PubMed ID: 2472634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.
    Jacobsen H; Ahlborn-Laake L; Gugel R; Mous J
    J Virol; 1992 Aug; 66(8):5087-91. PubMed ID: 1378515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
    Eriksson BF; Schinazi RF
    Antimicrob Agents Chemother; 1989 May; 33(5):663-9. PubMed ID: 2546487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.
    Ichimura H; Levy JA
    Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
    Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT
    J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
    Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characterization of EIAV reverse transcriptase and its inhibition by 5'-triphosphates of 2'-deoxyuridine analogs, PFA and PAA.
    Tao P; Zhang X; Quan K
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):130-4. PubMed ID: 1711694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
    Mellors JW; Dutschman GE; Im GJ; Tramontano E; Winkler SR; Cheng YC
    Mol Pharmacol; 1992 Mar; 41(3):446-51. PubMed ID: 1372083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.
    Koshida R; Vrang L; Gilljam G; Harmenberg J; Oberg B; Wahren B
    Antimicrob Agents Chemother; 1989 May; 33(5):778-80. PubMed ID: 2526616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
    EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
    Cox S; Koshida R; Harmenberg J; Wahren B
    Adv Enzyme Regul; 1991; 31():85-97. PubMed ID: 1715118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of human immunodeficiency virus type 1 (HIV-1) replication and accumulation of viral DNA in HIV-1-infected T cells blocked in cell replication.
    Tang S; Poulin L; Levy JA
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():933-9. PubMed ID: 1634879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
    Selvam MP; Blay RA; Geyer S; Buck SM; Pollock L; Mayner RE; Epstein JS
    AIDS Res Hum Retroviruses; 1993 May; 9(5):475-81. PubMed ID: 7686387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of foscarnet against viral polymerases.
    Crumpacker CS
    Am J Med; 1992 Feb; 92(2A):3S-7S. PubMed ID: 1371038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
    Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
    Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of azidothymidine to inhibit human immunodeficiency virus (HIV) replication in a promonocytic cell line (U937).
    Uherová P; Schmidtmayerová H; Mayer V
    Acta Virol; 1991 Aug; 35(4):357-64. PubMed ID: 1724875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase.
    Lowe DM; Parmar V; Kemp SD; Larder BA
    FEBS Lett; 1991 May; 282(2):231-4. PubMed ID: 1709876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.